

# George Kunos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8037329/publications.pdf>

Version: 2024-02-01

33  
papers

8,679  
citations

201674

27  
h-index

414414

32  
g-index

34  
all docs

34  
docs citations

34  
times ranked

8007  
citing authors

#	ARTICLE	IF	CITATIONS
1	Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?. Journal of Clinical Investigation, 2022, 132, .	8.2	2
2	Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. Journal of Clinical Investigation, 2021, 131, .	8.2	85
3	Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia. Molecules, 2021, 26, 5089.	3.8	4
4	Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets. Hepatology, 2020, 72, 412-429.	7.3	100
5	The therapeutic potential of second and third generation CB1R antagonists. , 2020, 208, 107477.		84
6	Interactions Between Alcohol and the Endocannabinoid System. Alcoholism: Clinical and Experimental Research, 2020, 44, 790-805.	2.4	32
7	Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis. Cell Metabolism, 2019, 30, 877-889.e7.	16.2	68
8	Alcohol Binge-Induced Cardiovascular Dysfunction Involves Endocannabinoid-CB1-R Signaling. JACC Basic To Translational Science, 2019, 4, 625-637.	4.1	9
9	Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis. Cell Metabolism, 2019, 29, 1320-1333.e8.	16.2	42
10	Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity. JACC: Cardiovascular Imaging, 2018, 11, 320-332.	5.3	24
11	Î-caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice. British Journal of Pharmacology, 2018, 175, 320-334.	5.4	68
12	Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes. Diabetes, 2017, 66, 994-1007.	0.6	40
13	Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice. Molecular Metabolism, 2017, 6, 1517-1528.	6.5	30
14	Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences, 2015, 36, 277-296.	8.7	524
15	Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology, 2014, 59, 143-153.	7.3	139
16	Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nature Medicine, 2013, 19, 1132-1140.	30.7	347
17	Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18832-18837.	7.1	63
18	Chronic alcohol produces neuroadaptations to prime dorsal striatal learning. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14783-14788.	7.1	172

#	ARTICLE	IF	CITATIONS
19	Hepatic Cannabinoid Receptor-1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in Mice. <i>Gastroenterology</i> , 2012, 142, 1218-1228.e1.	1.3	155
20	Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance. <i>Cell Metabolism</i> , 2012, 16, 167-179.	16.2	302
21	Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. <i>Psychopharmacology</i> , 2010, 208, 37-44.	3.1	66
22	Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. <i>Journal of Clinical Investigation</i> , 2010, 120, 2953-2966.	8.2	393
23	Paracrine Activation of Hepatic CB1 Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver. <i>Cell Metabolism</i> , 2008, 7, 227-235.	16.2	280
24	Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 3160-3169.	8.2	399
25	Genetic Impairment of Frontocortical Endocannabinoid Degradation and High Alcohol Preference. <i>Neuropsychopharmacology</i> , 2007, 32, 117-126.	5.4	147
26	Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H1689-H1695.	3.2	107
27	The Endocannabinoid System as an Emerging Target of Pharmacotherapy. <i>Pharmacological Reviews</i> , 2006, 58, 389-462.	16.0	2,274
28	Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. <i>Journal of Clinical Investigation</i> , 2005, 115, 1298-1305.	8.2	847
29	Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. <i>Journal of Clinical Investigation</i> , 2005, 115, 1298-1305.	8.2	494
30	Lipopolysaccharide Induces Anandamide Synthesis in Macrophages via CD14/MAPK/Phosphoinositide 3-Kinase/NF- $\kappa$ B Independently of Platelet-activating Factor. <i>Journal of Biological Chemistry</i> , 2003, 278, 45034-45039.	3.4	203
31	Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1393-1398.	7.1	319
32	Presynaptic Specificity of Endocannabinoid Signaling in the Hippocampus. <i>Neuron</i> , 2001, 31, 453-462.	8.1	497
33	Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. <i>Nature Medicine</i> , 2001, 7, 827-832.	30.7	363